SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: IRWIN JAMES FRANKEL who wrote (14610)12/9/2004 6:21:29 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
In an effort to hang onto its lucrative franchise, Kos filed for and won FDA approval for a new formulation of Niaspan. That formulation is expected to launch in late 2005, with Kos actively working to migrate patients from Niaspan and any generic competitors to its new formulation of the drug.

Maybe I missed this, but I haven't the faintest idea of what he is talking about. Anyone else heard about this?

Peter